AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 91 min read$PHVS

Lu Peng sold $610K of PHVS

Lu Peng (President) sold 15,000 shares of Pharvaris N.V. (PHVS) at $40.68 ($0.61M total) on 2026-09-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lu Peng
Published Sep 9, 2026, 3:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 3:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PHVS
Bearish
medium confidence
Mentioned
$PHVS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider sentiment for PHVS, a micro‑cap biotech.

02

Market read

First‑hand insider sale information that may influence short‑term trading decisions for PHVS.

03

What to watch

Holding after sale remains 65,179 shares, indicating continued confidence despite the partial divestiture.

Relevance 4/10Novelty 6/10Timing: same‑day filing

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$PHVSBearishMedium confidence
Context

President Lu Peng sold 15,000 shares for $610,134 via a 10b5‑1 plan on Sep 8, 2026.

Expected impact

Potential modest downside pressure over the next few days.

Evidence & confidence

The sale is sizable for a micro‑cap biotech and executed through a pre‑arranged plan, suggesting a neutral to slightly bearish impact.

Market effects

Sector

May raise concerns for other small‑cap biotech stocks if insider sales become frequent.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Minimal global impact.

Counterpoint

What could challenge this read

The sale was pre‑arranged under a 10b5‑1 plan, which may not reflect current sentiment; the stock could be undervalued.

Key entities

  • Company
    Pharvaris N.V.

    Biotech firm listed on NASDAQ under ticker PHVS.

  • Executive
    Lu Peng

    President of Pharvaris N.V. and reporting officer.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PHVS insider trading history →

Related articles

OCT 8
$PHVSMedAI 8/10

Pharvaris HAE drug shows faster symptom relief in Lancet study

Pharvaris' phase 3 study of deucrictibant IR for HAE attacks, published in The Lancet, met all endpoints, showing faster symptom relief and resolution than placebo. The drug was well-tolerated. FDA and EMA reviews are ongoing with decisions expected in 2027. According to the company, the study results support the drug's efficacy and safety.

investing.com5 min
OCT 8
$PHVSMedAI 8/10

Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet

Pharvaris (PHVS) announced positive results from the RAPIDe-3 study of deucrictibant IR for treating HAE attacks, published in The Lancet. The treatment showed rapid symptom relief and resolution, with a well-tolerated safety profile. The company's NDA and MAA for deucrictibant IR are under regulatory review, with a PDUFA target date of April 23, 2027.

globenewswire.com5 min